In 2024, North America held a dominan market position, capturing more than a 39.4% share, holding USD 0.52 Billion revenue.
Sanofi has secured regulatory approval in China for two innovative medicines, Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia syndrome. The approvals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback